Data Insights

U-51 by Shanghai Unicar-Therapy Bio-Medicine Technology for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval

U-51 is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Idiopathic Thrombocytopenic Purpura (Immune...

Likelihood of Approval and Phase Transition Success Rate Model - U-51 in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Data Insights

CD19 and BCMA CAR T-Cells by Shanghai Unicar-Therapy Bio-Medicine Technology for Leukemia: Likelihood of Approval

CD19 and BCMA CAR T-Cells is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for...

Likelihood of Approval and Phase Transition Success Rate Model - CD19 And BCMA CAR T-Cells in Leukemia

Data Insights

CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Acute Lymphocytic Leukemia...

Likelihood of Approval and Phase Transition Success Rate Model - CD19/CD22 CAR-T in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

U-01 by Shanghai Unicar-Therapy Bio-Medicine Technology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

U-01 is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Relapsed Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - U-01 in Relapsed Acute Myeloid Leukemia

Data Insights

U-01 by Shanghai Unicar-Therapy Bio-Medicine Technology for Refractory Acute Myeloid Leukemia: Likelihood of Approval

U-01 is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Refractory Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - U-01 in Refractory Acute Myeloid Leukemia

Data Insights

CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Primary Mediastinal B-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - CD19/CD22 CAR-T in Primary Mediastinal B-Cell Lymphoma

Data Insights

CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for B-Cell Non-Hodgkin Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - CD19/CD22 CAR-T in B-Cell Non-Hodgkin Lymphoma

Data Insights

CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for Follicular Lymphoma: Likelihood of Approval

CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Follicular Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - CD19/CD22 CAR-T in Follicular Lymphoma

Data Insights

CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for Mantle Cell Lymphoma: Likelihood of Approval

CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Mantle Cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - CD19/CD22 CAR-T in Mantle Cell Lymphoma

Data Insights

CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Diffuse Large B-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - CD19/CD22 CAR-T in Diffuse Large B-Cell Lymphoma

Data Insights

CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for B-Cell Acute Lymphocytic...

Data Insights

Humanized CD19 CAR-T Cells by Shanghai Unicar-Therapy Bio-Medicine Technology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Humanized CD19 CAR-T Cells is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Acute...

Data Insights

U-87 by Shanghai Unicar-Therapy Bio-Medicine Technology for Solid Tumor: Likelihood of Approval

U-87 is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase I for Solid Tumor. According to...

Data Insights

CAR-T Cell Therapy by Shanghai Unicar-Therapy Bio-Medicine Technology for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

CAR-T Cell Therapy is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Diffuse Large...

Likelihood of Approval and Phase Transition Success Rate Model - CAR-T Cell Therapy in Diffuse Large B-Cell Lymphoma

Data Insights

PD-1 Silent PSMA or PSCA Targeted CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

PD-1 Silent PSMA or PSCA Targeted CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase...

Likelihood of Approval and Phase Transition Success Rate Model - PD-1 Silent PSMA Or PSCA Targeted CAR-T in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

U-01 by Shanghai Unicar-Therapy Bio-Medicine Technology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

U-01 is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase I for B-Cell Acute Lymphocytic Leukemia...